A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.